Mackenzie Financial Corp Affimed N.V. Transaction History

Mackenzie Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$7.78 - $11.4 $576,731 - $845,082	-74,130 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$5.12 - $8.48 $44,339 - $73,436	-8,660 Reduced 10.46%	74,130 $586,000
Q4 2020 Feb 10, 2021	BUY	$3.16 - $7.03 $210,424 - $468,127	66,590 Added 411.05%	82,790 $482,000
Q1 2020 May 14, 2020	BUY	$1.44 - $3.02 $23,328 - $48,924	16,200 New	16,200 $25,000
Q3 2019 Nov 14, 2019	SELL	$2.67 - $3.65 $44,055 - $60,225	-16,500 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.6 - $4.21 $42,900 - $69,465	16,500 New	16,500 $47,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.